A Phase 2, Randomized, Controlled, Multicenter, Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy
This study includes multiple formulations for formulation selection of the fixed-combination product and for the factorial design assessment of the contribution of each component. HTX-011A is the second formulation studied (HTX-011-49). HTX-011B is the final formulation studied (HTX-011-56), which was also included in subsequent Phase 2b and Phase 3 studies. For the factorial design assessment, HTX-002, a bupivacaine-only formulation in the same HTX-011 proprietary polymer, and HTX-009, a meloxicam-only formulation in the same HTX-011 proprietary polymer, were evaluated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
430
HTX-011A (bupivacaine/meloxicam), via injection.
Saline placebo via injection.
HTX-011B (bupivacaine/meloxicam), via injection or instillation.
Unnamed facility
Anaheim, California, United States
Unnamed facility
Bakersfield, California, United States
Unnamed facility
Pasadena, Maryland, United States
Unnamed facility
Houston, Texas, United States
Unnamed facility
Mean Summed Pain Intensity (SPI) Score Over 24 Hours
The SPI is derived by summing the pain intensity score weighted by the scheduled time duration. SPI0-24 will be calculated by summing the Pain intensity (PI) score at the relevant time points weighted by the scheduled time duration since the prior PI assessment as follows: SPI0-24= PI1+PI2+2\*PI4+2\*PI6+2\*PI8+2\*PI10+2\*PI12+2\*PI14+4\*PI18+6\*PI24. Min = 0 (if PI=0 at every time) and Max = 240 (if PI=10 at every time).
Time frame: 0-24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
HTX-002, via injection.
Bupivacaine HCI, via injection.
HTX-009, via injection.
San Antonio, Texas, United States